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Abstract
Although human cytomegalovirus (HCMV) is generally not regarded to be an oncogenic virus, HCMV infection has
been implicated in malignant diseases from different cancer entities. On the basis of our experimental findings,
we developed the concept of “oncomodulation” to better explain the role of HCMV in cancer. Oncomodulation
means that HCMV infects tumor cells and increases their malignancy. By this concept, HCMV was proposed to
be a therapeutic target in a fraction of cancer patients. However, the clinical relevance of HCMV-induced onco-
modulation remains to be clarified. One central question that has to be definitively answered is if HCMV estab-
lishes persistent virus replication in tumor cells or not. In our eyes, recent clinical findings from different groups in
glioblastoma patients and especially the detection of a correlation between the numbers of HCMV-infected glio-
blastoma cells and tumor stage (malignancy) strongly increase the evidence that HCMVmay exert oncomodulatory
effects. Here, we summarize the currently available knowledge about the molecular mechanisms that may con-
tribute to oncomodulation by HCMV as well as the clinical findings that suggest that a fraction of tumors from
different entities is indeed infected with HCMV.
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Introduction
Human cytomegalovirus (HCMV) is a ubiquitous herpes virus that
leads to a life-long persistence. The frequency of infection ranges from
50% to 100% in the general adult population. Human cytomegalo-
virus causes severe and often fatal disease in immunocompromised in-
dividuals including recipients of organ transplants and AIDS patients.
It routinely reactivates in healthy virus carriers, but this is usually con-
trolled by the host immune response [1–3]. Monocytes may be an im-
portant reservoir for latent HCMV; however, the primary reservoir may
be a more primitive cell from the myeloid lineage. Reactivation may
result from cellular differentiation or inflammation [1–3].
The (possible) relationship between HCMV infection and cancer
has been investigated for decades (for review see, e.g., [1]). Detection
of viral DNA, mRNA, and/or antigens in tumor tissues as well as
seroepidemiologic evidence suggested a role of HCMV infection in
the etiology of several human malignancies.
In the 1970s, the group of Fred Rapp reported HCMV to trans-
form normal human embryonal cells in vitro [4,5]. Although the
transformed cell lines exhibited enhanced tumorigenicity in nude
mice, the expression of HCMV-specific antigens in the transformed
and tumor-derived lines decreased with increasing passage [6]. In
later studies using normal rodent cells, HCMV (infectious virus or
virus DNA) was shown to induce mutations in genes that are critical
for malignant transformation [7–10]. However, viral DNA was not
detected in most transformants. These findings led to the speculation
that HCMV contributes to oncogenesis by “hit-and-run” mechanism
[7–10]. However, this scenario is difficult to prove because it sup-
poses that virus nucleic acids are not retained in transformed cells.
In fact, up to now, there is no conclusive evidence for the transfor-
mation of normal cells after HCMV infection in humans, and the
mechanism by which HCMV might contribute to oncogenesis re-
mains obscure. Today, it is generally accepted that infection of normal
permissive cells with HCMV does not result in malignant transforma-
tion (cells actively expressing virus no longer divide and eventually
die), so that the virus is not considered to be oncogenic.
Twelve years ago, we proposed the concept of oncomodulation
in which HCMV may favor tumor progression without being an
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oncogenic virus to explain the frequent presence of HCMV in tumor
tissues [11]. Oncomodulation means that HCMV may infect tumor
cells and modulate their malignant properties, in a fashion not in-
volving direct transformation. We postulated that tumor cells provide
a genetic environment, characterized by disturbances in intracellular
signaling pathways, transcription factors, and tumor suppressor pro-
teins, that enables HCMV to exert its oncomodulatory potential,
although it cannot be manifested in normal cells. To study these ef-
fects, we established persistently HCMV-infected cancer cell lines
(see, e.g., [11–14]). Studies in these cell lines demonstrated that
long-term persistent HCMV infection is necessary to fully express onco-
modulatory effects. Subcutaneous injection of persistently HCMV-
infected neuroblastoma cells resulted in increased malignant behavior
as indicated by enhanced tumor growth and metastasis formation
compared to noninfected cells [11]. Moreover, we identified HCMV
as a potential therapeutic target for patients with HCMV-infected
tumors [11,13,14].
Human cytomegalovirus–induced oncomodulation may result
from the activity of virus regulatory proteins and noncoding RNA,
which influence properties of tumor cells including cell proliferation,
survival, invasion, production of angiogenic factors, and immuno-
genicity. As a result, HCMV infection may lead to a shift to a more
malignant phenotype of tumor cells and tumor progression [1,14].
The clinical relevance of these experimental findings remains a mat-
ter of debate. We will first briefly summarize the molecular mecha-
nisms that may underlie HCMV-induced oncomodulation before we
discuss the current evidence concerning its clinical relevance.
Molecular Mechanisms of
HCMV-Induced Oncomodulation
Influence of HCMV on the Cell Cycle of Cancer Cells
In normal permissive cells, HCMV-encoded regulatory proteins
induce cell cycle arrest and prevent cellular DNA replication but
maintain an active state that enables replication of viral DNA
[15,16]. In HCMV-infected cells, the expression of the cyclins D1
and A is inhibited, although hallmarks of S-phase, including pRB
hyperphosphorylation, cyclin E and cyclin A kinase activation, and
expression of many S-phase genes are present.
Several HCMV regulatory proteins such as the 72-kDa immediate
early-1 (IE1-72), 86-kDa IE2-86, and the tegument protein pp71
were shown to interact and inactivate proteins of the Rb family
(pRb, p107, and p130) promoting entry into S phase of the cell cycle.
Moreover, the UL97 protein was shown to exert cyclin-dependent ki-
nase activity resulting in phosphorylation and inactivation of pRb [17].
Conversely, HCMV IE2-86 may induce cell cycle arrest by activating
an ataxia telangiectasia mutated gene–dependent phosphorylation of
p53 at Ser15. These events result in p53 accumulation and activation,
leading to a p53- and p21-dependent inhibition of cell cycle progres-
sion [18]. Other virus regulatory proteins, for example, the pUL69,
contribute to HCMV-induced cell cycle arrest [15].
In tumor cells, cell cycle is commonly deregulated [19,20]. In cells
with disrupted cell cycle control mechanisms (such as tumor cells),
the function of virus regulatory proteins may depend on the internal
context of tumor cells [14] (Figure 1). In normal fibroblasts express-
ing wild-type p53, HCMV IE1-72 protein cannot drive cells out of
quiescence, whereas IE1-72 can induce S phase and delay cell cycle
exit in p53-deficient cells. Human cytomegalovirus IE2-86 protein
induces a G1/S block in human cells with wild-type pRb, but not
in the human Rb-deficient osteosarcoma cell line Saos-2. In T89G
glioblastoma cells with disrupted p53 signaling, persistent HCMV in-
fection did not induce cell cycle arrest and virus antigen-positive cells
continued to divide [21]. In experiments using a panel of human glio-
blastoma cell lines, a stable expression of IE1-72 was shown to dif-
ferentially affect cell growth, resulting either in cell proliferation or
in arrest. In U87 and U118 glioblastoma cells, IE1-72–induced pro-
liferation was paralleled by reduction in steady state expression levels
of pRb and p53 family (including p53, p63, or p73) members. In
contrast, IE1-72 expression in LN229 and U251 glioblastoma cells
was associated with increased expression of p53 family proteins, ac-
companied by growth arrest [22]. The HCMV protein US28 promoted
cell cycle progression and cyclin D1 expression in cells with a tumori-
genic phenotype, whereas it induced apoptosis in nontumorigenic
cells [23].
Figure 1. Major effects of HCMV on regulators of tumor cell cycle and/or apoptosis. CDK, cyclin-dependent kinase; E2F, E2F transcrip-
tion factor; MDM2, mouse double minute 2.
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It has also been shown that persistent HCMV infection of tumor
cells may lead to a selection of novel virus variants characterized by
changes in coding sequences for virus regulatory proteins that have
lost their ability to induce cell cycle arrest. Human cytomegalovirus
persistent infection of tumor cells including glioblastoma and osteo-
sarcoma results in the development of mutated virus variants, which
grow slowly and yield lower amounts of progeny virus compared to
wild-type virus strains originally used for infection [24,25]. These
HCMV variants were found to have DNA deletions in their genome
and synthesized IE protein different in size from those of the wild-
type virus strain. Moreover, stable expression of HCMV IE2-86
protein in retrovirus-transduced fibroblasts did not abrogate the G1
checkpoint owing to a mutation within a critical carboxyl-terminal
domain of IE2-86 protein, thus making it unable to halt cell cycle
progression [26]. Infection of fibroblasts with an HCMV strain con-
taining a deletion in the UL69 gene failed to induce a block in the
G1/S phase of the cell cycle [27]. These findings demonstrate that the
effects of HCMV on cell cycle and cell proliferation may depend
both on the context of the internal cellular environment and on
the properties of virus regulatory proteins.
Influence of HCMV on Cancer Cell Apoptosis
Resistance to apoptosis is a common feature of cancer cells and
represents a relevant chemoresistance mechanism [19,20,28–30].
The first study on HCMV infection and apoptosis revealed that
HCMV protects fibroblasts from apoptosis induced by adenovirus
E1A protein [31]. Moreover, the HCMV IE1-72 and IE2-86 proteins
inhibited apoptosis induced by the adenovirus E1A and TNF-α but
not by irradiation with UV light in cervix carcinoma HeLa cells [31].
The authors speculated that HCMV exerts its antiapoptotic effects
through IE proteins by both p53-independent and p53-dependent
mechanisms. In fact, other investigators revealed that, in some cells,
HCMV IE2-86 binds to p53, inhibits its transactivating function,
and protects from p53-mediated apoptosis under conditions that
would otherwise induce the pathway [32–36] (Figure 1). IE2-86 in-
hibited doxorubicin-induced apoptosis in smooth muscle cells, indi-
cating that IE2-86 can suppress p53-mediated apoptosis after DNA
damage [35]. Furthermore, ts13 cells with a temperature-sensitive mu-
tation in TAFII250 do not undergo p53-dependent apoptosis when
IE2-86 is expressed and the cells are grown at the nonpermissive tem-
perature [36].
Direct antiapoptotic activity of HCMV proteins was ascribed mainly
to some distinct transcripts encoded by the HCMV UL36-UL38
genes [37,38]. The product of UL36, a viral inhibitor of caspase ac-
tivation, binds to the prodomain of caspase-8, thus inhibiting Fas-
mediated apoptosis [39,40]. The UL37 gene product, UL37 exon 1
(UL37x1), a viral mitochondrial inhibitor of apoptosis, inhibits the re-
cruitment of the proapoptotic endogenous Bcl-2 family member Bax
and Bak to mitochondria, resulting in their functional neutralization
[41,42]. Notably, cervix carcinoma HeLa cells expressing the viral
mitochondrial inhibitor of apoptosis were resistant to apoptosis trig-
gered by doxorubicin. The HCMV UL38 gene encodes a protein that
protects infected cells from apoptosis induced by a mutant adenovirus
lacking the antiapoptotic E1B-19K protein or by thapsigargin, which
disrupts calcium homeostasis in the endoplasmic reticulum [43]. In
cells infected with wild type virus, pUL38 was shown to interact with
tuberous sclerosis tumor suppressor protein complex resulting in a fail-
ure to regulate the mammalian target of rapamycin complex 1 [44].
Viral 2.7-kb noncoding RNA (β2.7) inhibited apoptosis in infected
U373 glioma cells subjected to mitochondrial stress by stabilizing
the mitochondrial respiratory chain complex I [45].
Human cytomegalovirus infection was shown to protect tumor
cells from apoptosis by the induction of cellular proteins, including
AKT, Bcl-2, and ΔNp73α [13,14]. Human cytomegalovirus binding
to its cellular receptors such as integrins initiates activation of AKT
through the phosphatidylinositol 3-kinase (PI3K) pathway. More-
over, stable expression of the IE1-72 protein was sufficient to sus-
tain increased AKT activity in glioblastoma cells independently of
virus receptor signaling [22]. Recently, HCMV glycoprotein B was
shown to bind to the platelet-derived growth factor receptor (PDGFR)
and to initiate activation of AKT through the PI3K pathway in dif-
ferent cell types including U87 glioma cells [46] (Figure 2). Further-
more, HCMV activated AKT by selective phosphorylation of the
upstream nonreceptor cellular kinase focal adhesion kinase (FAK)
at Tyr397, in glioblastoma and prostate carcinoma cell lines [47,48].
Activation of other signaling pathways including those mediated by
mitogen-activated protein kinase (MAPK) kinase (MEK) 1/2 or the
c-Jun NH2-terminal kinase (JNK) may be induced through viral regu-
latory proteins and/or binding of HCMV glycoproteins to PDGFR
or virus coreceptors including integrins and Toll-like receptor 2
[1,46]. These complex events may result in gene transcription, which
alters apoptotic responses and other malignant properties of tumor
cells (Figure 2).
Increased expression of the antiapoptotic protein Bcl-2 and de-
creased sensitivity to chemotherapeutic agents were reported in
HCMV-infected neuroblastoma and colon carcinoma cell lines
[13,49]. Other observations showed that HCMV infection induced
accumulation of the ΔNp73α isoform in glioblastoma and neuroblas-
toma cell lines [50,51]. Human cytomegalovirus–induced ΔNp73α
exerted a dominant-negative effect on p73α- and p53-dependent
apoptosis in both p53-negative and p53 wild type tumor cells [50]
(Figure 1). In persistently infected neuroblastoma cells, HCMV de-
creased the expression of p73 with a concomitant increase in N-myc
expression, suggesting that HCMV could also enable neuroblas-
toma cells to escape the apoptotic properties of p73 through N-myc–
dependent pathway [50].
Influence of HCMV on Cancer Cell Invasion, Migration,
and Adhesion to the Endothelium
Cancer cell invasion, migration, and adhesion to the endothelium
play important roles during formation of metastases [52–54]. Neuro-
blastoma cells persistently infected with HCMV expressed increased
motility and adhesion to human endothelial cells [1]. The increased
adhesion to endothelium was mediated by activation of β1α5 integrin
on a surface of infected tumor cells, which led to a focal disruption
of endothelial cell integrity, thus facilitating tumor cell transmigration.
Moreover, HCMV downregulated neural cell adhesion molecule
(NCAM; CD56) receptors in persistently infected neuroblastoma cells
contributing to augmented tumor cell adhesion and transendothelial
penetration [51]. The effects of HCMV on NCAM also account for
decreased adhesion of cancer cells to each other, which is presumably
one of the first steps in metastasis. The inhibitory effects of HCMVon
NCAM expression may stem from the suppression of p73 expression
in infected cells, resulting in decreased transactivation of the NCAM
promoter by p73.
In human prostate cancer PC-3 cells, HCMV infection upregu-
lated tumor cell adhesion to the endothelium and to extracellular
matrix proteins. This process was accompanied by the enhancement
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of β1-integrin surface expression, elevated levels of integrin-linked
kinase, and phosphorylation of FAK at Tyr397 [47]. In human ma-
lignant glioma cells, HCMV infection also increased extracellular
matrix–dependent migration and invasion in dependence on FAK
phosphorylation at Tyr397 [48]. These effects were not observed in
normal astroglial cells, suggesting that HCMV can selectively augment
glioma invasiveness.
US28 protein, a G protein–coupled chemokine receptor encoded
by HCMV, induces arterial smooth muscle cell migration by a
ligand-dependent process [55]. It has been shown that US28 signals
through the non–receptor protein tyrosine kinases Src and FAK and
that this activity is necessary for US28-mediated smooth muscle cell
migration [56]. It is of interest to show whether the US28 pathway
may contribute to FAK activation and stimulation of cell invasion
observed in HCMV-infected tumor cells.
Investigation of gene expression in several persistently HCMV-
infected neuroblastoma cell lines by gene microarray revealed up-
regulation of genes that are involved in cancer cell invasion [57].
Influence of HCMV on Angiogenesis
Recruitment of tumor vessels is an integral part of cancer initia-
tion and progression [19,58,59]. US28 protein, a G protein–coupled
chemokine receptor encoded by HCMV, induced a proangiogenic
and transformed phenotype in mouse fibroblast NIH-3T3 cells
through up-regulation of vascular endothelial factor [23]. US28-
expressing cells were tumorigenic in nude mice. Expression of a G
protein–uncoupled constitutively inactive mutant of US28 delayed
and attenuated tumor formation, indicating a role of constitutive
receptor activity in the onset of tumor development. Importantly,
US28 was also shown to be involved in HCMV-induced angio-
genesis in glioblastoma cells infected with a clinical HCMV strain
through the induction of vascular endothelial factor production.
Moreover, expression of interleukin 8 (IL-8), another well-recognized
promoter of tumor angiogenesis, was stimulated by HCMV infection
in leukemia and glioma cells [60,61]. Human cytomegalovirus–
induced IL-8 expression may be caused by the ability of the HCMV
IE1-72 protein to transactivate the IL-8 promoter through the cellu-
lar transcription factors NF-κB and AP-1 [61]. In addition, HCMV
infection of glioma cells suppressed the expression of angiogenesis
inhibitors, such as thrombospondins 1 and 2, through the activity
of IE proteins without the involvement of p53 [62,63].
Human cytomegalovirus infection of endothelial cells resulted in
proangiogenic effects mediated through virus binding to and signaling
through integrin β1, integrin β3, and epidermal growth factor receptor
[64]. Secretome analysis of HCMV-infected cells revealed enhanced
levels of proangiogenic molecules as well as increased proangiogenic
activity of cell-free supernatants [65]. By this mechanism, tumor cells
themselves as well as nontransformed stroma cells (e.g., fibroblasts or
endothelial cells) may contribute to cancer progression.
Influence of HCMV on Cancer Cell Immunogenicity
The ability to evade from recognition by the immune system is es-
sential for cancer cells [66,67]. The HCMV proteins US2, US3, US6,
and US11 decrease cell surface expression of major histocompatibility
complex (MHC) class I or class II proteins, which may help infected
cells to avoid adaptive immune response [68,69] (Figure 3A). The
HCMV-encoded protein UL16 provides protection against detection
by immune cells through preventing the MHC class I–related chain B,
UL16 binding proteins 1 and 2 from reaching the cell surface, whereas
HCMV microRNA (miR-UL112) prevents expression of MHC class
I–related chain B in infected cells [68,70,71]. MHC class I–related
chain B and UL16 binding proteins are cellular ligands for the activat-
ing receptor NKG2D, which is expressed on some natural killer (NK)
cells, γ/σ T cells, and CD8+ cells. Other HCMV-encoded proteins
Figure 2. Major signaling pathways activated by HCMV binding to the PDGFR and/or by HCMV immediate early (IE) proteins that may
contribute to oncomodulation by HCMV. Akt, murine thymoma viral (v-akt) oncogene homolog-1 (protein kinase B); ERK, extracellular signal–
regulated kinase; IKK, inhibitor of NF-κB kinase; JNK, c-junN-terminal kinase;MEK,MAPK/ERK kinase;MEKK,MEK kinase;mTOR,mammalian
target of rapamycin; NF-κB, nuclear factor κB; p70S6K, 70-kDa ribosomal S6 kinase; PI3K, phosphatidylinositol-3-kinase.
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such as MHC class I homolog UL18 and UL40 may inhibit NK re-
sponses against infected cells by triggering NK inhibitory CD94/
NKG2A receptor [71] (Figure 3B). The potential contribution of
such oncomodulatory mechanisms to tumor progression was shown
in a murine cytomegalovirus (MCMV) model. Expression of the
MCMV-encoded class I homolog m144 protected lymphoma cells
from NK cell lysis resulting in increased tumor growth and decreased
survival in a syngeneic mouse model [72].
Human cytomegalovirus–infected tumor cells may avoid immune
responses also by production of immunosuppressive cytokines. The
HCMV-encoded viral IL-10 homolog (UL111a; cmvIL-10) exerts
potent immunosuppressive properties similar to those of IL-10 pro-
duced by human cells [73–75]. During latent infection, the UL111a
region transcript undergoes alternative splicing, which results in the
expression of latency-associated cmvIL-10. The latency-associated
cmvIL-10 retains some, but not all, of the immunosuppressive func-
tions of cmvIL-10 and its expression may enable HCMV to avoid
immune recognition and clearance during latency [75]. This may be
of relevance for tumor cells with limited permissiveness for HCMV.
Moreover, HCMV stimulated the production of the cellular immune
suppressive cytokine transforming growth factor β1 (TGF-β1) in dif-
ferent tumor cell types including glioblastoma, leukemia, and osteo-
sarcoma cells [76,77]. Interestingly, TGF-β1 is regarded to be the
most prominent glioblastoma-associated immunosuppressant [78].
Moreover, TGF-β1 itself had already been shown to stimulate HCMV
replication in cultured cells [79]. A comparative study of the influence
of HCMV infection and IE protein expression on TGF-β1 promoter
function in permissive cells pointed to a possible cooperative role be-
tween IE proteins and protein(s) expressed during the early phase of
viral infection [76]. In the human glioma cell line U373, the HCMV
IE2-86 protein regulates transcription of the TGF-β1 gene by its abil-
ity to interact with the Egr-1 DNA-binding protein [80]. In addition,
Figure 3. Immune escape mechanisms mediated by HCMV in tumor cells. (A) Influence of HCMV gene products cytotoxic T-cell lysis in
tumor cells, (B) influence of HCMV gene products (and microRNA) on natural killer cell lysis in tumor cells. MHC, major histocom-
patibility complex; TGF-β, transforming growth factor β.
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HCMV was shown to induce integrin αvβ6 expression in endothelial
cells of different tissues in patients with HCMV infection. The expres-
sion of integrin αvβ6 in HCMV-infected cells promoted activation of
TGF-β1 from its secreted biologically inactive form [81]. Therefore,
HCMV may influence individual infected cells, surrounding tissues,
and/or immune reactions through TGF-β1 production and/or activa-
tion. This may promote virus replication and interfere with host im-
mune responses against tumor cells.
Influence of HCMV on Chromosome Stability
Human cytomegalovirus infection has been demonstrated to in-
duce chromosome damage [82], and genetic instability is considered
to be major driver of cancer progression [83,84]. In 1972, chromo-
some damage induced by HCMV infection in human cells was re-
ported for the first time [85]. Human cytomegalovirus infection in
combination with cytotoxic agents synergistically increased genotoxic
effects [86,87]. Most notably, HCMV was shown to induce spe-
cific chromosome 1 strand breaks at positions 1q42 and 1q21 in a
replication-independent manner [88]. The possible targets residing
near 1q42 include the ADPRT locus involved in DNA repair and
replication [89] whose deletion has been connected to the develop-
ment of glioblastoma [90]. A breast cancer tumor suppressor gene
was proposed to be located at 1q21-31 [91], therefore representing
a potential target of 1q21 strand breaks.
Human cytomegalovirus IE1-72 and IE2-86 gene products can
cooperate with the adenovirus E1A protein to transform primary
baby rat kidney (BRK) cells [9]. The finding that many of the trans-
formed BRK cell lines contained mutated p53 alleles suggest that
mutation of p53 might be one of the mechanisms by which IE pro-
teins contribute to transformation. Because HCMV proteins and
DNA were not present in cell lines derived from the transformed
BRK foci, it has been suggested that HCMV could contribute to
oncogenesis by “hit-and-run” mechanism [9]. In addition, three dif-
ferent cell lines transformed by HCMV were shown to harbor an
activating mutation in both alleles in H-Ras [8]. However, in both
cases, it is unclear whether the mutations in H-Ras or p53 are a di-
rect result of the mutagenic activity of HCMV gene products. The
mutations could arise as the transformants are selected for growth
in culture.
Clinical Findings
Although HCMV infection of tumor cells was initially reported
30 years ago in patients with carcinomas such as prostate or colon
cancer, later pathologic investigations provided conflicting results
[14]. A renewed interest in the role of HCMV in cancer diseases was
promoted by recent studies using highly sensitive techniques for virus
detection which indicated the presence of genome and antigens, of
HCMV in tumor cells (but not in adjacent normal tissue) of more
than 90% of patients with certain malignancies, such as colon cancer,
malignant glioma, prostate carcinoma, and breast cancer [3,49,92–96].
These pathologic observations demonstrated that HCMV causes low-
grade infections in tumor cells probably sustained by persistent virus
replication. To further understand whether HCMV infection in tumors
is of clinical relevance, patients with malignant glioblastoma were
grouped according to the level of HCMV-infected tumor cells. Re-
markably, patients with low levels lived almost twice as long as pa-
tients with high levels suggesting that HCMV infection of tumor
cells alters the disease course in this patient group [3]. Moreover, de-
tection of HCMV in different histologic types of gliomas revealed that
HCMV-positive cells in glioblastoma multiforme were 79% compared
to 48% in lower grade tumors [96]. Recent clinical studies also dem-
onstrated the presence of HCMV DNA in the peripheral blood of a
high percentage of glioblastoma patients (80%) but not in the blood
of healthy control individuals [94]. These results suggest either a sys-
temic reactivation of HCMV within patients with glioblastoma (which
may be relevant for virus transport from periphery into the tumor
tissues) or shedding of viral DNA after reactivation of latent HCMV
in tumor cells into the periphery. Although HCMV viremia exerts
subclinical character in glioblastoma patients, it may be relevant for
the transport of HCMV into tumor tissues by immune cells such as
monocytes/macrophages. A secondary reactivation of virus may be
caused by cancer-related and/or treatment-related immunosuppression.
In fact, a pilot clinical study showed that the incidence of HCMV re-
activation in patients receiving conventional chemotherapy (without
major immunosuppressive agents) may be high without obvious
HCMV disease [94]. It should also be noted that HCMV reactivation
seems to be dependent on differentiation of myeloid lineage and in-
flammation [2,3]. In patients with different inflammatory disorders,
HCMV reactivation was evident in inflamed tissues but not in non-
inflamed tissue specimens from the same patient or healthy controls
[3]. Therefore, inflammatory environment present in most solid tumors
could contribute to local HCMV reactivation. Conversely, HCMV also
exerts proinflammatory potential mainly owing to the production of
numerous inflammatory mediators from infected cells [14]. Thus,
HCMVreactivation in cancer tissues may enhance tumor inflammation
and accelerate a malignant process.
Conclusions
Many clinical and experimental findings suggest a contribution of
HCMV to malignancy and chemoresistance of infected tumor cells
from different entities. However, oncomodulation needs to be fur-
ther defined in a systematic manner to increase the understanding
of the phenomenon and to better translate the experimental results
in more effective anticancer therapies. First, standardization of highly
sensitive techniques is necessary to detect low-grade HCMV infec-
tion of tumor tissues to reasonably compare pathologic studies from
different groups. Moreover, the clinical relevance of experimentally
defined oncomodulatory mechanisms induced by HCMV regulatory
proteins and noncoding RNA needs to be examined. This includes
the investigation of the HCMV oncomodulatory activity in the con-
text of the internal cellular environment in tumor tissues and ge-
netic and functional studies of HCMV strains isolated from patients’
tumor samples. Hereby, it is important to study HCMV-induced
oncomodulation not only in infected tumor cells but also in stroma
cells, because HCMV-induced changes in the tumor microenviron-
ment may also contribute to oncomodulation. Another central aim is
to develop therapeutic strategies to suppress HCMV replication or
to target viral regulatory proteins or noncoding RNA because persis-
tent virus replication is supposed to be essential for oncomodula-
tion. Clinical trials to evaluate the efficacy of antiviral treatment or
HCMV-targeted immunotherapy in patients with malignant glio-
blastoma have just been started [3,94]. Most recently, an HCMV-
specific CD8+ T-cell response was induced in a glioblastoma patient
after therapeutic vaccination with dendritic cells pulsed with autol-
ogous tumor lysate [95]. This finding supports that HCMV may be
a potential immunotherapeutic target in HCMV-infected tumors and
should therefore be a further impulse to strengthen our efforts.
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